**Description**

**A COMPOSITION FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS**

**Technical Field**

The invention relates to a composition formed for the treatment of the sexual dysfunctions.

**State of the Art**

Reduction of sexual desire may be expressed as the reduction in the frequency of sexual intercourse, failure to perceive sufficient attractiveness in the partner or simply the lack of desire. When examined, the individual is found to have no or very few thoughts or fantasies about sex, to pay no attention to the sexual stimulus and to have very little interest in beginning a sexual experience.

The sexual dysfunctions in the men develop with organic or psychological origin. Heart and coronary insufficiency, hypertension, diabetes and neurological disorders are the first organic causes coming to the mind. Hypertension, high triglyceride levels and high cholesterol as well as atherosclerosis, i.e. the vessel stiffness, which develops due to these conditions, cause vessel blockage. The effects of this blockage emerge firstly and especially in the vessels of the penile region. The reason is that the vessels in this region have a diameter of several millimeters, in other words, they are very thin. This causes the condition of inadequate erection, i.e. the problem of erection. Problem of erection is seen in one out of every 10 men and the blockage of the penile vessels emerges as the primary reason for the erection problem particularly in the men at the age of 50 and older.

The invention no. WO 1998/007422 entitled "Therapeutic treatment for sexual dysfunctions" discloses a method for treating sexual dysfunctions, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione, particularly its hydrochloride, or mesylate salt.

Also, the invention no. EP1392697B1 entitled "Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline" discloses that the compounds of the invention are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction and related illnesses.

Also, the invention no. TR2011/05399 entitled "Use of 3,7-bis(2-hydroxyethyl) icaritin component for the treatment of erectile dysfunction and the defects in the sperm production” relates to the use of 3,7-bis(2-hydroxyethyl)icaritin, a structurally altered analogue of the flavonoid icaritin, for the treatment of sex disorders and the erectile dysfunction and sperm production defects.

As a result, the presence of the need for a composition for treating the sexual dysfunctions and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to elevate the cavernous nitric oxide level, thereby supporting the erection.

Another object of the invention is to increase the sexual desire.

Another object of the invention is to reduce the release of prolactin.

Another object of the invention is to suppress the release of prolactin.

Another object of the invention is to support the erection owing to the ability to simultaneously elevate cAMP and cGMP and also provide an increase in the sexual pleasure owing to the increased blood circulation in the reproductive organs.

In order to achieve the aforesaid advantages, the invention is a composition for treating the sexual dysfunctions, said composition being obtained by the components selected from the group comprising methylsalidroside and 20-(S)-B-ginsenoside rg3 that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition formed for the treatment of the sexual dysfunctions.

Ginsenoside rg3, an ingredient of the composition according to the invention, elevates the cavernous nitric oxide level, thereby supporting the erection. Methylsalidroside, the other ingredient, increases the sexual desire and reduces the release of prolactin, owing to its dopaminergic property. Also, ginsenoside Rg3 suppresses the release of prolactin. Also, ginsenoside rg3 supports the erection owing to its ability to simultaneously elevate cAMP and cGMP and also provides an increase in the sexual pleasure owing to the increased blood circulation in the reproductive organs.

The composition according to the invention contains methylsalidroside and 20-(S)-B-ginsenoside rg3. Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:

20-80% methylsalidroside,

80-20% 20-(S)-B-ginsenoside rg3.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for treating the sexual dysfunctions and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for treating the sexual dysfunctions, said composition being obtained by the components selected from the group comprising methylsalidroside and 20-(S)-B-ginsenoside rg3 that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 20-80% by weight methylsalidroside.
3. A composition according to Claim 1 characterized in that it comprises 80-20% by weight 20-(S)-B-ginsenoside rg3.
4. Use of the components according to Claims 1 to 3 obtained individually or in combinations from the group consisting of methylsalidroside and 20-(S)-B-ginsenoside rg3 for the manufacture of a composition for treating the sexual dysfunctions.

**ABSTRACT**

**A COMPOSITION FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS**

The invention relates to a composition formed for the treatment of the sexual dysfunctions.

No figure.